文献速递主动脉疾病内脏/肾动脉与血管畸形

使用现成开窗分支支架治疗胸腹主动脉瘤后两年靶血管相关结局

Two-year target vessel-related outcomes following use of off-the-shelf branched endografts for the treatment of thoracoabdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2023-04-11

这项上市后观察性研究在三个欧洲中心纳入80例胸腹主动脉瘤患者,使用现成Zenith t-Branch支架及桥接支架行血管内修复,随访至2年。24个月时全因死亡免除率为78.5%,动脉瘤相关死亡免除率为98.6%,腹腔干、肠系膜上动脉、左肾动脉、右肾动脉的一期通畅率免除率分别为94.8%、100%、91.3%、89.3%。

要点

  • 24个月全因死亡免除率78.5%,动脉瘤相关死亡免除率98.6%。
  • 24个月腹腔干、肠系膜上动脉、左肾动脉、右肾动脉一期通畅率免除率分别为94.8%、100%、91.3%、89.3%。
  • 12个月后84.6%(44/52)患者动脉瘤最大直径缩小>5 mm,11.5%(6/52)增大>5 mm。

核心结论

  • 在症状性或无症状性胸腹主动脉瘤患者中,t-Branch支架治疗后2年靶血管一期和二期通畅率显示修复持久。

研究设计与样本

  • 上市后观察性研究,2012年至2017年在三个欧洲中心双向入组,共80例患者接受t-Branch支架及桥接支架血管内修复胸腹主动脉瘤,随访至2年。

主要发现

  • 技术成功率为98.8%(79/80),中位随访22.2个月(四分位距9.2-25.1个月)。
  • 24个月Kaplan-Meier全因死亡免除率为78.5%,动脉瘤相关死亡免除率为98.6%。
  • 12个月后影像随访中,84.6%(44/52)患者动脉瘤最大直径缩小>5 mm,3.8%(2/52)不变,11.5%(6/52)增大>5 mm。
  • 24个月腹腔干、肠系膜上动脉、左肾动脉、右肾动脉一期通畅率免除率分别为94.8%、100%、91.3%、89.3%;二期通畅率免除率分别为96.3%、100%、98.2%、98.3%。
  • 共298根靶血管,研究期间12根闭塞;24个月二次干预免除率为76.3%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to assess clinical outcomes and target vessel patency through 2 years following thoracoabdominal aortic aneurysms (TAAA) repair with the off-the-shelf Zenith t-Branch Thoracoabdominal Endovascular Graft (William Cook Europe). METHODS: This post-market observational study was conducted at three European sites with ambispective enrollment from 2012 to 2017. Patients underwent endovascular TAAA repair with the t-Branch graft and bridging stent grafts (BSGs) for the celiac (CA), superior mesenteric (SMA), left renal (LRA), and/or right renal (RRA) arteries. Follow-up was through 2 years, per sites' standard of care. Procedural and 1-year results were reported previously. RESULTS: Eighty patients (mean age, 71.0±7.4 years; 70.0% men) were enrolled; six patients had symptomatic TAAAs, and 15 patients had contained ruptures. Technical success was achieved in 98.8% of patients (79/80). Median follow-up was 22.2 months (interquartile range, 9.2-25.1 months). At 24 months, Kaplan-Meier (KM) freedom from all-cause and aneurysm-related mortality were 78.5% and 98.6%, respectively. Beyond 12 months, 38 adverse events occurred in 20 patients, including two aortic ruptures (one study aneurysm and one non-study aneurysm) and six deaths (none aneurysm-related, as reported by the site). Compared with postprocedure, maximum aneurysm diameter decreased (>5 mm) in 84.6% (44/52), remained unchanged in 3.8% (2/52), and increased (>5 mm) in 11.5% (6/52) of patients with imaging follow-up after 12 months. No conversions to open repair, and no t-Branch graft or other endograft component migration or integrity issues were reported. No loss of patency was reported in the t-Branch or iliac limb grafts throughout the study. Throughout study duration, four patients had five imaging-reported BSG compressions, none of which required secondary intervention. KM freedom from secondary intervention was 76.3% at 24 months. Fourteen target vessel-related secondary interventions were performed, primarily consisting of stent placement for endoleak, stenosis, or occlusion. KM freedom from loss of primary patency was 94.8%, 100%, 91.3%, and 89.3% for the CA, SMA, LRA, and RRA, respectively, at 24 months. KM freedom from loss of secondary patency in the CA, SMA, LRA, and RRA were 96.3%, 100%, 98.2%, and 98.3% at 24 months, respectively. A total of 298 vessels were targeted, of which 12 were occluded over the study period. CONCLUSIONS: Primary and secondary target vessel patency rates through 2 years demonstrated durable repair with the t-Branch graft in patients treated for symptomatic or asymptomatic thoracoabdominal aortic aneurysms.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tsilimparis N, Bosiers M, Resch T, et al. Two-year target vessel-related outcomes following use of off-the-shelf branched endografts for the treatment of thoracoabdominal aortic aneurysms. J Vasc Surg. 2023. PMID: 37044318. doi:10.1016/j.jvs.2023.03.498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。